Search research articles
Contact Us
Filters
Showing results (421-430 of 439) with videos related to
Page
of 44
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
February 5, 2003
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains
Christopher A Willoughby, Keith G Rosauer, Jeffery J Hale, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV
Christopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 5, 2004
Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists
K Shankaran, Karla L Donnelly, Shrenik K Shah, et al.
BMC Public Health
|
November 5, 2021
Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort
R J Fredericksen, B M Whitney, E Trejo, et al.
Science (New York, N.Y.)
|
September 24, 2011
Impacts of the Cretaceous Terrestrial Revolution and KPg extinction on mammal diversification
Robert W Meredith, Jan E Janečka, John Gatesy, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment
Min Shu, Jennifer L Loebach, Kerry A Parker, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds
Dong-Ming Shen, Min Shu, Christopher A Willoughby, et al.
Organic Letters
|
July 5, 2003
CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity
Christopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Physiological Genomics
|
November 22, 2012
11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature
Mingjuan J Luo, Rolf Thieringer, Martin S Springer, et al.
The Journal of Experimental Medicine
|
August 17, 2005
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice
Anne Hermanowski-Vosatka, James M Balkovec, Kang Cheng, et al.
Page
of 44
Search research articles
Search
Showing results (421-430 of 439) with videos related to
Sort By:
Page
of 44
Bioorganic & Medicinal Chemistry Letters
|
February 5, 2003
1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains
Christopher A Willoughby, Keith G Rosauer, Jeffery J Hale, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 25, 2002
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV
Christopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 5, 2004
Syntheses and biological evaluation of 5-(piperidin-1-yl)-3-phenyl-pentylsulfones as CCR5 antagonists
K Shankaran, Karla L Donnelly, Shrenik K Shah, et al.
BMC Public Health
|
November 5, 2021
Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort
R J Fredericksen, B M Whitney, E Trejo, et al.
Science (New York, N.Y.)
|
September 24, 2011
Impacts of the Cretaceous Terrestrial Revolution and KPg extinction on mammal diversification
Robert W Meredith, Jan E Janečka, John Gatesy, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment
Min Shu, Jennifer L Loebach, Kerry A Parker, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 12, 2004
Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds
Dong-Ming Shen, Min Shu, Christopher A Willoughby, et al.
Organic Letters
|
July 5, 2003
CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity
Christopher L Lynch, Jeffrey J Hale, Richard J Budhu, et al.
Physiological Genomics
|
November 22, 2012
11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature
Mingjuan J Luo, Rolf Thieringer, Martin S Springer, et al.
The Journal of Experimental Medicine
|
August 17, 2005
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice
Anne Hermanowski-Vosatka, James M Balkovec, Kang Cheng, et al.
Page
of 44